Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-(2-[18F]fluoroethyl)-L-Tyrosine, commonly known as 18F-FET, is a radiolabeled synthetic amino acid used as a positron emission tomography (PET) imaging tracer. Labeled with the radioactive isotope fluorine‑18, it is primarily utilized in neuro-oncology for diagnosing, treatment planning, and monitoring of brain tumors such as gliomas. The compound is actively transported into tumor cells via the L-type amino acid transporter system but is not incorporated into proteins or readily degraded. This results in high intracellular concentrations within tumor cells and enables detailed metabolic imaging of tumors. Compared to standard PET tracers like 18F-fluorodeoxyglucose (FDG), which can be less sensitive for brain tumors due to high background uptake in normal brain tissue, 18F-FET offers improved specificity for detecting malignant lesions and distinguishing them from inflammatory tissue[1][2][10]. It has also shown selective uptake in squamous cell carcinomas outside the central nervous system[6]. The agent's favorable pharmacokinetics and stability make it suitable for clinical use in PET imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on O-(2-[18F]fluoroethyl)-L-tyrosine.